Modern Management of Acute Myocardial Infarction

Antman, 2004, ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction), J Am Coll Cardiol, 44, 1, 10.1016/j.jacc.2004.07.014 McGovern, 1996, Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors, N Engl J Med, 334, 884, 10.1056/NEJM199604043341403 Roger, 2002, Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979 to 1994, Ann Intern Med, 136, 341, 10.7326/0003-4819-136-5-200203050-00005 DeWood, 1980, Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction, N Engl J Med, 303, 897, 10.1056/NEJM198010163031601 DeWood, 1986, Coronary arteriographic findings soon after non-Q-wave myocardial infarction, N Engl J Med, 315, 417, 10.1056/NEJM198608143150703 Yamaji, 2001, Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography, J Am Coll Cardiol, 38, 1348, 10.1016/S0735-1097(01)01563-7 Alpert, 2000, Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, J Am Coll Cardiol, 36, 959, 10.1016/S0735-1097(00)00804-4 Adams, 1994, Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I, N Engl J Med, 330, 670, 10.1056/NEJM199403103301003 Galvani, 1997, Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina, Circulation, 95, 2053, 10.1161/01.CIR.95.8.2053 Newby, 1998, Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes, Circulation, 98, 1853, 10.1161/01.CIR.98.18.1853 Ohman, 1996, Cardiac troponin T levels for risk stratification in acute myocardial ischemia, N Engl J Med, 335, 1333, 10.1056/NEJM199610313351801 Hamm, 1992, The prognostic value of serum troponin T in unstable angina, N Engl J Med, 327, 146, 10.1056/NEJM199207163270302 Wallentin, 2000, Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease, Lancet, 356, 9, 10.1016/S0140-6736(00)02427-2 Wu, 1999, National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases, Clin Chem, 45, 1104, 10.1093/clinchem/45.7.1104 Killip, 1967, Treatment of myocardial infarction in a coronary care unit, Am J Cardiol, 20, 457, 10.1016/0002-9149(67)90023-9 1988, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 2, 349 Lau, 1992, Cumulative meta-analysis of therapeutic trials for myocardial infarction, N Engl J Med, 327, 248, 10.1056/NEJM199207233270406 Freemantle, 1999, Beta blockade after myocardial infarction: systematic review and meta regression analysis, BMJ, 318, 1730, 10.1136/bmj.318.7200.1730 Roberts, 1991, Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction, Circulation, 83, 422, 10.1161/01.CIR.83.2.422 2005, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, Lancet, 366, 1622 Faxon, 2004, Beta-blocker therapy and primary angioplasty: what is the controversy?, J Am Coll Cardiol, 43, 1788, 10.1016/j.jacc.2004.03.001 Jugdutt, 1988, Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications, Circulation, 78, 906, 10.1161/01.CIR.78.4.906 Jugdutt, 1981, Effect of intravenous nitroglycerin on collateral blood flow and infarct size in the conscious dog, Circulation, 63, 17, 10.1161/01.CIR.63.1.17 Antman, 2006, Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction, N Engl J Med, 354, 1477, 10.1056/NEJMoa060898 Van de Werf, 2001, Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction, Lancet, 358, 605, 10.1016/S0140-6736(01)05775-0 Van de Werf, 2002, Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options, Circulation, 105, 2813, 10.1161/01.CIR.0000019762.35104.DA Ribichini, 2002, Acute myocardial infarction: reperfusion treatment, Heart, 88, 298, 10.1136/heart.88.3.298 Gersh, 2005, Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?, JAMA, 293, 979, 10.1001/jama.293.8.979 1997, A comparison of reteplase with alteplase for acute myocardial infarction, N Engl J Med, 337, 1118, 10.1056/NEJM199710163371603 1999, Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial, Lancet, 354, 716, 10.1016/S0140-6736(99)07403-6 Keeley, 2003, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials, Lancet, 361, 13, 10.1016/S0140-6736(03)12113-7 De Luca, 2004, Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts, Circulation, 109, 1223, 10.1161/01.CIR.0000121424.76486.20 Nallamothu, 2003, Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?, Am J Cardiol, 92, 824, 10.1016/S0002-9149(03)00891-9 Kastrati, 2004, Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled Trial, JAMA, 291, 947, 10.1001/jama.291.8.947 Van de Werf F. ASSENT 4, European Society of Cardiology Congress, Stockholm, Sweden, 2005. Le May, 2005, Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study), J Am Coll Cardiol, 46, 417, 10.1016/j.jacc.2005.04.042 Gershlick, 2005, Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction, N Engl J Med, 353, 2758, 10.1056/NEJMoa050849 Fernandez-Aviles, 2004, Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial, Lancet, 364, 1045, 10.1016/S0140-6736(04)17059-1 Quinn, 1999, Ticlopidine and Clopidogrel, Circulation, 100, 1667, 10.1161/01.CIR.100.15.1667 Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Weitz, 1995, New antithrombotics, Chest, 108, 471S, 10.1378/chest.108.4_Supplement.471S 1988, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 332, 349, 10.1016/S0140-6736(88)92833-4 Antman, 1999, Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial, Circulation, 99, 2720, 10.1161/01.CIR.99.21.2720 2000, Trial of abciximab with and without low-dose reteplase for acute myocardial infarction, Circulation, 101, 2788, 10.1161/01.CIR.101.24.2788 Topol, 2001, Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial, Lancet, 357, 1905, 10.1016/S0140-6736(00)05059-5 Giugliano, 2003, Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic trial, J Am Coll Cardiol, 41, 1251, 10.1016/S0735-1097(03)00123-2 Zorman, 2002, Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty, Am J Cardiol, 90, 533, 10.1016/S0002-9149(02)02530-4 Arntz, 2003, Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study, Eur Heart J, 24, 268, 10.1016/S0195-668X(03)94640-9 Mesquita Gabriel, 2003, Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial, Eur Heart J, 24, 543, 10.1016/S0195-668X(03)95631-4 Lee, 2003, Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial, Circulation, 107, 10.1161/01.CIR.0000056120.00513.7A Cutlip, 2003, Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction, Am J Cardiol, 92, 977, 10.1016/S0002-9149(03)00983-4 van’t Hof, 2004, on behalf of the On-TIME study group, Eur Heart J, 25, 837 Cutlip, 2001, Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes, Am J Cardiol, 88, 62, 10.1016/S0002-9149(01)01587-9 Zeymer, 2005, Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial, Eur Heart J, 10.1093/eurheartj/ehi293 Montalescot, 2004, Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis, JAMA, 292, 362, 10.1001/jama.292.3.362 Mehta, 2003, Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention, J Am Coll Cardiol, 42, 1739, 10.1016/j.jacc.2003.07.012 Kenner, 1995, Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up, Am J Cardiol, 76, 861, 10.1016/S0002-9149(99)80250-1 Ito, 1996, Clinical implications of the ‘no reflow’ phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction, Circulation, 93, 223, 10.1161/01.CIR.93.2.223 Braunwald, 2002, ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina), J Am Coll Cardiol, 40, 1366, 10.1016/S0735-1097(02)02336-7 Swedberg, 1992, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction, N Engl J Med, 327, 678, 10.1056/NEJM199209033271002 1994, GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction, Lancet, 343, 1115 1995, ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction, Lancet, 345, 669, 10.1016/S0140-6736(95)90865-X 1995, Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1), Lancet, 345, 686, 10.1016/S0140-6736(95)90866-8 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 Kober, 1995, A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821 Ambrosioni, 1995, The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction, N Engl J Med, 332, 80, 10.1056/NEJM199501123320203 Kingma, 1994, Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction, Eur Heart J, 15, 898, 10.1093/oxfordjournals.eurheartj.a060608 LaRosa, 1999, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA, 282, 2340, 10.1001/jama.282.24.2340 Ray, 2005, The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes, J Am Coll Cardiol, 46, 1425, 10.1016/j.jacc.2005.05.086 Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med, 349, 1893, 10.1056/NEJMoa032292 Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207 Antman, 2000, The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. doi;10.1001/jama.284.7.835, JAMA, 284, 835, 10.1001/jama.284.7.835 1996, Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group, Lancet, 347, 561, 10.1016/S0140-6736(96)91270-2 Goodman, 2000, Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study, J Am Coll Cardiol, 36, 693, 10.1016/S0735-1097(00)00808-1 Antman, 1999, Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction, Circulation, 100, 1602, 10.1161/01.CIR.100.15.1602 1999, Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study, Lancet, 354, 701, 10.1016/S0140-6736(99)07350-X 1999, Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome), Eur Heart J, 20, 1553, 10.1053/euhj.1999.1879 2006, Comparison of fondaparinux and enoxaparin in acute coronary syndromes, N Engl J Med, 354, 1464, 10.1056/NEJMoa055443 1998, A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, N Engl J Med, 338, 1498, 10.1056/NEJM199805213382103 1998, Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction, N Engl J Med, 338, 1488, 10.1056/NEJM199805213382102 1998, Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy, N Engl J Med, 339, 436, 10.1056/NEJM199808133390704 2002, Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes, Circulation, 105, 316, 10.1161/hc0302.102573 1998, International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network, Circulation, 97, 2386, 10.1161/01.CIR.97.24.2386 Simoons, 2001, Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial, Lancet, 357, 1915, 10.1016/S0140-6736(00)05060-1 Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345 Hongo, 2002, The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting, J Am Coll Cardiol, 40, 231, 10.1016/S0735-1097(02)01954-X Kastrati, 2006, Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 Randomized Trial, JAMA, 295, 1531, 10.1001/jama.295.13.joc60034 McCullough, 1998, A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy, J Am Coll Cardiol, 32, 596, 10.1016/S0735-1097(98)00284-8 Boden, 1998, Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy, N Engl J Med, 338, 1785, 10.1056/NEJM199806183382501 1999, Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study, Lancet, 354, 708, 10.1016/S0140-6736(99)07349-3 Cannon, 2001, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban, N Engl J Med, 344, 1879, 10.1056/NEJM200106213442501 Fox, 2002, Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial, Lancet, 360, 743, 10.1016/S0140-6736(02)09894-X de Winter, 2005, Early invasive versus selectively invasive management for acute coronary syndromes, N Engl J Med, 353, 1095, 10.1056/NEJMoa044259 Nishimura, 1986, Early repair of mechanical complications after acute myocardial infarction, JAMA, 256, 47, 10.1001/jama.1986.03380010051023 Nishimura, 1983, Papillary muscle rupture complicating acute myocardial infarction: analysis of 17 patients, Am J Cardiol, 51, 373, 10.1016/S0002-9149(83)80067-8 Chen, 2002, Mitral valve surgery for acute papillary muscle rupture following myocardial infarction, J Heart Valve Dis, 11, 27 Honan, 1990, Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis, J Am Coll Cardiol, 16, 359, 10.1016/0735-1097(90)90586-E Kinn, 1997, Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction, Cathet Cardiovasc Diagn, 42, 151, 10.1002/(SICI)1097-0304(199710)42:2<151::AID-CCD12>3.0.CO;2-R Becker, 1996, A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction, J Am Coll Cardiol, 27, 1321, 10.1016/0735-1097(96)00008-3 Purcaro, 1997, Diagnostic criteria and management of subacute ventricular free wall rupture complicating acute myocardial infarction, Am J Cardiol, 80, 397, 10.1016/S0002-9149(97)00385-8 Becker, 1999, Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists—observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study, J Am Coll Cardiol, 33, 479, 10.1016/S0735-1097(98)00582-8 Solodky, 2001, Comparison of incidence of cardiac rupture among patients with acute myocardial infarction treated by thrombolysis versus percutaneous transluminal coronary angioplasty, Am J Cardiol, 87, 1105, 10.1016/S0002-9149(01)01471-0 Moreno, 2002, Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction, J Am Coll Cardiol, 39, 598, 10.1016/S0735-1097(01)01796-X Hochman, 2001, One-year survival following early revascularization for cardiogenic shock, JAMA, 285, 190, 10.1001/jama.285.2.190 Slater, 2000, Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry, J Am Coll Cardiol, 36, 1117, 10.1016/S0735-1097(00)00845-7 Lopez-Sendon, 1992, Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria, J Am Coll Cardiol, 19, 1145, 10.1016/0735-1097(92)90315-E Montoya, 1980, Early repair of ventricular septal rupture after infarction, Am J Cardiol, 45, 345, 10.1016/0002-9149(80)90657-8 Scanlon, 1985, Urgent surgery for ventricular septal rupture complicating acute myocardial infarction, Circulation, 72 Padro, 1988, Sutureless repair of postinfarction cardiac rupture, J Card Surg, 3, 491, 10.1111/j.1540-8191.1988.tb00442.x Lachapelle, 2002, Sutureless patch technique for postinfarction left ventricular rupture, Ann Thorac Surg, 74, 96, 10.1016/S0003-4975(02)03581-6 Frances, 1998, Left ventricular pseudoaneurysm, J Am Coll Cardiol, 32, 557, 10.1016/S0735-1097(98)00290-3 Yeo, 1999, Clinical characteristics and outcome in postinfarction pseudoaneurysm, Am J Cardiol, 84, 592, 10.1016/S0002-9149(99)00385-9 Birnbaum, 2000, Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction, Am J Cardiol, 86, 830, 10.1016/S0002-9149(00)01101-2 Lemery, 1992, Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention, Am J Cardiol, 70, 147, 10.1016/0002-9149(92)91266-7 Crenshaw, 2000, Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction, Circulation, 101, 27, 10.1161/01.CIR.101.1.27 Labrousse, 2002, Surgery for post infarction ventricular septal defect (VSD): risk factors for hospital death and long term results, Eur J Cardiothorac Surg, 21, 725, 10.1016/S1010-7940(02)00054-4 Landzberg, 1998, Transcatheter management of ventricular septal rupture after myocardial infarction, Semin Thorac Cardiovasc Surg, 10, 128, 10.1016/S1043-0679(98)70006-1 Archbold, 1998, Frequency and prognostic implications of conduction defects in acute myocardial infarction since the introduction of thrombolytic therapy, Eur Heart J, 19, 893, 10.1053/euhj.1997.0857 Rathore, 2001, Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes, Am Heart J, 141, 47, 10.1067/mhj.2001.111259 Harpaz, 1999, Complete atrioventricular block complicating acute myocardial infarction in the thrombolytic era, J Am Coll Cardiol, 34, 1721, 10.1016/S0735-1097(99)00431-3 Berger, 1992, Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II, J Am Coll Cardiol, 20, 533, 10.1016/0735-1097(92)90004-7 Goodfellow, 1995, Reversal of atropine-resistant atrioventricular block with intravenous aminophylline in the early phase of inferior wall acute myocardial infarction following treatment with streptokinase, Eur Heart J, 16, 862, 10.1093/oxfordjournals.eurheartj.a061008 Woods, 1992, Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2), Lancet, 339, 1553, 10.1016/0140-6736(92)91828-V Go, 1998, Bundle-branch block and in-hospital mortality in acute myocardial infarction, Ann Intern Med, 129, 690, 10.7326/0003-4819-129-9-199811010-00003 Brilakis, 2001, Bundle branch block as a predictor of long-term survival after acute myocardial infarction, Am J Cardiol, 88, 205, 10.1016/S0002-9149(01)01626-5 Crenshaw, 1997, Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience, J Am Coll Cardiol, 30, 406, 10.1016/S0735-1097(97)00194-0 Pedersen, 1999, The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction, Eur Heart J, 20, 748, 10.1053/euhj.1998.1352 Rathore, 2000, Acute myocardial infarction complicated by atrial fibrillation in the elderly—prevalence and outcomes, Circulation, 101, 969, 10.1161/01.CIR.101.9.969 Al-Khatib, 2001, Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial, Am J Cardiol, 88, 76, 10.1016/S0002-9149(01)01593-4 Goldberg, 2002, Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective, Am Heart J, 143, 519, 10.1067/mhj.2002.120410 Widimsky, 2003, Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial—PRAGUE-2, Eur Heart J, 24, 10.1016/S0195-668X(02)00468-2 Grines, 2002, A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the air primary angioplasty in myocardial infarction study, J Am Coll Cardiol, 39, 1713, 10.1016/S0735-1097(02)01870-3 Andersen, 2003, A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction, N Engl J Med, 349, 733, 10.1056/NEJMoa025142 Klein, 1997, Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease, Circulation, 96, 61, 10.1161/01.CIR.96.1.61 Cohen, 1997, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease, N Engl J Med, 337, 447, 10.1056/NEJM199708143370702 Antman, 1999, Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction, Circulation, 100, 1593, 10.1161/01.CIR.100.15.1593 Verheugt, 1999, Acute coronary syndromes: drug treatments, Lancet, 353